| InMed Pharmaceuticals Inc. |
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 |
| Balance Sheet Date | | | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fiscal Period | | | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price to Sales | 1.10x | 1.07x | .80x | .51x | .68x | .64x | .48x | .39x | .39x | .50x | .75x | 1.39x | 1.00x | 3.57x | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forward Price to Sales MRQ | 1.04x | 1.01x | .76x | .50x | .74x | .63x | .43x | .46x | .44x | .66x | .33x | .88x | 1.00x | 4.69x | 2.27x | 10.76x | 17.87x | 4.63x | 7.09x | 13.25x | 20.83x | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price to Book | .40x | .39x | .30x | .36x | .53x | .38x | .24x | .20x | .17x | - | .26x | .29x | .13x | .55x | .79x | 1.22x | 1.34x | 1.07x | 3.38x | 2.23x | 3.04x | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Price to Earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Forward Price to Earnings MRQ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Debt to Asset Ratio | | | .14x | .24x | .27x | .20x | .22x | .17x | .16x | .12x | .14x | .16x | .15x | .25x | .29x | .30x | .27x | .12x | .25x | .16x | .35x | .32x | .25x | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Current Ratio | | | 6.99x | 3.49x | 3.05x | 5.07x | 4.41x | 6.58x | 7.03x | 6.19x | 5.66x | 5.22x | 5.84x | 3.52x | 2.89x | 2.13x | 2.71x | 8.29x | 3.78x | 6.36x | 4.76x | 2.73x | 3.77x | | | | | | | | | | | | | | | | | | | | | | | | | | |